Loss of RET-ROS at complex I induces diastolic dysfunction in mice that is reversed by aerobic exercise
Central to the development of heart failure with preserved ejection fraction (HFpEF) is the redox disruption of metabolic processes; however, the underlying mechanisms are not fully understood. This study utilized a murine model (ND6) carrying a homoplasmic mitochondrial DNA point mutation (<i>ND6 G13997A</i>), which maintains functional NADH oxidation but lacks the site-specific reactive oxygen species (ROS) generation via reverse electron transport (RET). We demonstrate that mice with RET-ROS deficiency have reduced exercise capacity despite higher lean body mass, impaired resilience to high-fat/high-sucrose dietary stress, and cardiac hypertrophy with diastolic dysfunction. Importantly, dobutamine-induced stress elevated succinate levels in the heart, accompanied by RET-ROS production in wild-type but not in ND6 mice. Furthermore, ND6 mice showed perturbation in metabolite profiles following dobutamine stress. Mechanistically, the ND6 heart had an upregulated expression of fatty acid transport, oxidation, and synthesis genes (<i>CD36</i>, <i>Cpt1b</i>, <i>Acly</i>, <i>Fas</i>, <i>Elovl6</i>, and <i>Scd1</i>) and increased protein levels of lipid metabolism regulators (acetyl-CoA carboxylase and perilipin 2). Interestingly, 8 wk of forced treadmill running increased acetyl-CoA abundance, alleviated metabolic stress, and improved diastolic function in RET-ROS mutant hearts. In summary, these findings reveal a critical role for RET-ROS in regulating exercise capacity and cardiometabolic health, identifying it as a potentially selective target for modulating cardiac metabolism.<b>NEW & NOTEWORTHY</b> Loss of reverse electron transport (RET)-reactive oxygen species (ROS) impairs diastolic function and exercise capacity, which can be improved by long-term aerobic exercise. RET-ROS may act as a modulator of cardiac metabolism.
Authors
- Alexis Díaz‐Vegas (ORCID: https://orcid.org/0000-0001-5227-4482)
- Daniel J. Fazakerley (ORCID: https://orcid.org/0000-0001-8241-2903)
- Keira Turner (ORCID: https://orcid.org/0000-0001-9586-9523)
- Jiro Abe (ORCID: https://orcid.org/0000-0002-3977-2679)
- Antonio Vidal‐Puig (ORCID: https://orcid.org/0000-0003-4220-9577)
- Andrew M. James (ORCID: https://orcid.org/0000-0002-0515-9649)
- Richard J. A. Goodwin (ORCID: https://orcid.org/0000-0001-5699-8488)
- Thomas Krieg (ORCID: https://orcid.org/0000-0002-5192-580X)
- Guillaume Bidault (ORCID: https://orcid.org/0000-0002-8396-9962)
- Xiaowen Duan (ORCID: https://orcid.org/0000-0003-1415-8899)
- Ana Vujić (ORCID: https://orcid.org/0000-0002-0559-5299)
- Amy Koo (ORCID: https://orcid.org/0000-0002-0318-1295)
- Joyce Valadares (ORCID: https://orcid.org/0000-0003-2230-7348)
- Michael P. Murphy (ORCID: https://orcid.org/0000-0003-1115-9618)
- Jan Lj. Miljković (ORCID: https://orcid.org/0000-0002-1910-9677)
- Andreas Dannhorn (ORCID: https://orcid.org/0000-0002-1087-4057)
- Jordan Lee (ORCID: https://orcid.org/0009-0008-6426-4896)
- Lowell E. Davis
Institutions
- The University of Sydney (AU)
- University of Cambridge (GB)
- AstraZeneca (Brazil) (BR)
- Centro de Investigacion Principe Felipe (ES)
Publication Details
- Journal
- American Journal of Physiology-Heart and Circulatory Physiology
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1152/ajpheart.00482.2024
- Citations
- 2
- Primary Topic
- Adipose Tissue and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 2.33
Funders
- Wellcome Trust
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- British Heart Foundation
- Medical Research Council